Pay attention here Boomers. The drunk Elf post yesterday was comical. Must have been drinking early. Affirmative action and DEI Doctors are problematic globally. Amarin has no sales team and the practice of medicine by physicians is as bad a it gets. Amarin is not successful in marketing their drug to clinicians since 2013 and has been doing a poor job for a decade. It’s bad enough reimbursement issues exist. But this is pathetic.
Triglyceride therapy was usually initiated at >1.7 mmol/L (>150 mg/dL), mainly with fibrates (71%).
How This Illustrates Poor Medical PracticeThis 71% fibrate dominance demonstrates a clear gap between evidence-based medicine and actual clinical behavior:• The 2026 ACC/AHA Dyslipidemia Guideline (and the 2025 ESC/EAS Focused Update) explicitly state that fibrates have no proven ASCVD benefit when added to statins.• The FDA’s October 2025 label revisions for fenofibrates reinforced this by citing multiple large trials (FIELD, ACCORD Lipid, PROMINENT) showing no reduction in cardiovascular morbidity or mortality.• Despite these clear signals, the majority of surveyed physicians continue to default to fibrates for moderate hypertriglyceridemia — a pattern driven by familiarity, low cost, and historical inertia rather than current outcome data.This is a textbook example of clinical inertia and guideline non-adherence. Physicians are not aligning therapy with the strongest available evidence (REDUCE-IT’s 25% MACE reduction with IPE) and are instead prescribing agents that guidelines now classify as having no cardiovascular benefit.Tie-Back to Vascepa and Our Broader DiscussionThis real-world data directly supports the commercial opportunity we have discussed:• The 2026 guideline positions IPE as “the only primary TG-lowering medication that reduces ASCVD event risk” in the exact population (persistent TG 150–499 mg/dL on statins).• Fenofibrate label changes and this INTERASPIRE evidence of 71% fibrate use create a strong case for step-therapy shifts toward IPE.• It reinforces the residual-risk narrative and the catalyst stack (guideline validation + clinical inertia) that Sarissa is leveraging for 2026 repricing and strategic exit.In short, the study confirms that a large segment of physicians are still practicing outdated medicine when it comes to TG management — precisely the gap that Vascepa’s evidence-based profile is positioned to fill.
AI
Market Data 
Markets 
